ASTRO Release: Memantine Delays Cognitive Decline in Brain Tumor Patients Who Receive Whole Brain Radiation Therapy

Published: Oct 29, 2012

BOSTON, Oct. 29, 2012 (GLOBE NEWSWIRE) -- Memantine, an N-Methyl-D-aspartate receptor antagonist typically prescribed to Alzheimer's patients, slows cognitive decline in brain cancer patients who receive whole brain radiation therapy (WBRT), according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 54th Annual Meeting.

Back to news